Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **right ventricle myocardium** refers to the muscular wall of the right ventricle, one of the four chambers of the human heart. Its primary role is to contract forcefully to propel deoxygenated blood from the right atrium through the tricuspid valve and into the pulmonary artery, sending blood to the lungs for oxygenation[1][3][5][7]. Structurally, the right ventricle's myocardium is thinner than that of the left ventricle due to its lower pressure workload, but it is highly specialized, with distinct papillary muscles, moderator band, and coarse trabeculations[1][3][5]. The tissue consists mainly of cardiomyocytes and connective tissue and is not a discrete molecular target, receptor, protein, or gene. Instead, it is a tissue or organ component, and as such, it is not classified as a conventional therapeutic target like enzymes, receptors, or ion channels. However, the right ventricle myocardium’s structure and molecular remodeling are critically important in conditions including heart failure, pulmonary hypertension, and congenital heart disease[4][5]. Molecular studies identify state-specific biomarkers and suggest that right ventricular dysfunction is associated with unique genetic, metabolic, and inflammatory profiles[2][4]. Targeted manipulation is indirect (e.g., via upstream signaling pathways, fibrosis, or cardiomyocyte metabolism) rather than direct drug-receptor interactions, and markers such as BNP and troponin are routinely used to assess right ventricle function and damage[2][4]. **Note:** - The "right ventricle myocardium" is an anatomical structure, not a single molecular entity or classic drug target (e.g., receptor, transporter, enzyme). Most drugs treat diseases affecting the tissue, not by directly targeting it as one targets a receptor[4][5]. - If the request was intended for a molecular target (such as a channel, gene, or receptor linked to right ventricle function or disease), a more specific name would be necessary. - As written, this is not a valid canonical therapeutic target in the traditional pharmacological sense, but a broader system/organ structure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Right ventricle myocardium.